Pacific Biosciences of California PACB Business Segments — Cost of revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:CostOfRevenue.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's business segments — cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacific Biosciences of California's business segments — cost of revenue?
- Pacific Biosciences of California (PACB) reported business segments — cost of revenue of $24.34M in Q1 2026.
- How has Pacific Biosciences of California's business segments — cost of revenue changed year-over-year?
- Pacific Biosciences of California's business segments — cost of revenue decreased by 36.8% year-over-year, from $38.52M to $24.34M.
- What is the long-term trend for Pacific Biosciences of California's business segments — cost of revenue?
- Over 3 years (2022 to 2025), Pacific Biosciences of California's business segments — cost of revenue has grown at a 12.9% compound annual growth rate (CAGR), from $79.27M to $114.23M.
- What does business segments — cost of revenue mean?
- This includes the direct costs associated with manufacturing, shipping, and supporting the sequencing platforms and consumables sold by the segment. Monitoring this helps evaluate the production efficiency and the direct margin impact of the company's core product offerings.